Removal of plasma porphyrins with high-flux hemodialysis in porphyria cutanea tarda associated with end-stage renal disease.
Plasma porphyrin levels are markedly increased in patients with porphyria cutanea tarda (PCT) associated with end-stage renal disease. Conventional hemodialysis (CHD) with lower blood flow rates (less than 250 mL/min) and cuprophan or cellulose acetate membranes is ineffective in removing significant amounts of porphyrins in this condition. Changes in plasma porphyrin levels and porphyrin clearances during hemodialysis with higher blood flow rates and more-permeable, high-efficiency cellulose acetate and high-flux polysulfone dialyzers were evaluated in a chronic hemodialysis patient with PCT and markedly elevated plasma porphyrins. The polysulfone membrane achieved significantly better fractional porphyrin removal (P = 0.02) and porphyrin clearances (P less than 0.01) than did the high-efficiency cellulose acetate membrane. After conversion from maintenance CHD with a standard cellulose acetate dialyzer to a 4-wk period of high-flux hemodialysis (HFHD) with a polysulfone dialyzer, predialysis plasma porphyrins fell by 37%. After returning to CHD, plasma porphyrins returned to the higher prestudy levels. These observations suggest that HFHD with more permeable membranes and higher blood flow rates removes porphyrins more effectively than does CHD. HFHD may be a useful adjunct to other measures used in treating dialysis patients with PCT.
Carson
R W
RW
Department of Internal Medicine, University of Texas Medical Branch, Galveston 77550.
Dunnigan
E J
EJ
DuBose
T D
TD
Goeger
D E
DE
Anderson
K E
KE
D002482:Cellulose / Q000031:analogs & derivatives; D005069:Evaluation Studies as Topic; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D008567:Membranes, Artificial; D010539:Permeability; D011108:Polymers; D011164:Porphyrias / Q000097:blood / Q000209:etiology / Q000628:therapy*; D011166:Porphyrins / Q000097:blood*; D006435:Renal Dialysis / Q000295:instrumentation / Q000379:methods; D012871:Skin Diseases / Q000097:blood / Q000209:etiology / Q000628:therapy*; D013450:Sulfones
D008567:Membranes, Artificial; D011108:Polymers; D011166:Porphyrins; D013450:Sulfones; C017662:polysulfone P 1700; C005062:acetylcellulose; D002482:Cellulose